Ongoing surveillance is only recommended if extensive gastric atrophy, intestinal metaplasia, or additional risk factors are identified
Limitations of a Symptom-Suppression Pain Model While medications and injections may reduce pain temporarily, they often: Do not correct structural imbalance or tissue degeneration Fail to resolve inflammatory or immune-driven pain Overlook metabolic contributors such as blood sugar instability or nutrient depletion Ignore nervous system sensitization and central pain amplification that perpetuate chronic pain As a result, pain frequently returnssometimes requiring higher doses, repeated injections, or additional medications to maintain relief
In group 1 (newly diagnosed diabetic group), there was no significant difference between the percentage of insulin-positive islets with pattern 1 and pattern 2 ( p = 0.09) and in insulin-negative islets between the same 2 patterns ( p = 0.80)
There is a lack of long-term effects data, including concerns about abnormal cell growth and the need for ongoing evaluation and monitoring
doi:10.1097/COC.0000000000000571
Prescription claims for Immunomodulator and Antiinflammatory drugs among persons with Ehlers-Danlos syndromes
